Michael Willem
University MunichMünchen, Germany
1470 RESULTS
University MunichMünchen, Germany
DZNEMunich, Germany
CNMGiza, Egypt
COMMENT As I reviewed these expert reactions to the FDA quasi-approval of aducanumab, I happened to also be reading the best-selling nonfiction book "Empire of Pain" by Patrick Keefe. It explains the machinations of the Sackler family, who took oxyconti
COMMENT I believe this is a terrible decision, probably the worst ever, by the only true policeman we have in the drug-development process. We always believed that clinical trials would be the ultimate arbiters of the avenues elaborated in the labs of scientists.
COMMENT I have a few questions for the experts here: 1. How do we measure slowing of clinical progression in each patient? Compare to clinical progression in the placebo group of the EMERGE trial? 2. How can the makers of donanemab be encouraged to do a head-to
COMMENT In our view, for a tau antibody to work, there are four major hurdles to overcome: (i) the blood-brain barrier, given that only an estimated 0.1 percent of peripherally administered therapeutic antibodies enter the brain; (ii) the plasma membrane of neuro
COMMENT We are very grateful for the helpful comments about the development of a blood-based biomarker panel for AD in the present stage. One comment is that clinically diagnosed AD is sometimes mixed with other types of dementia, including frontotemporal dementi
COMMENT The study of Norman and colleagues is an important contribution toward validating some of the commonly used methodological tools to capture brain-derived extracellular vesicles (EVs), particularly those derived from neurons. The study focuses on L1CAM,
COMMENT The study by Norman et al. concludes that L1CAM is not associated with extracellular vesicles (EVs) in human plasma or cerebrospinal fluid. The study assumes that all EVs contain tretraspanins, like classical exosomes. However, this assumption is not supp
COMMENT Lysosome-related organelles in the axons of intact and dystrophic brains Lysosomes are multifunctional, membrane-bound, acidic organelles that contain various acid hydrolases that degrade excess, old, and unneeded intracellular and extracellular materials
PAPER Waguri S, Dewitte F, Le Borgne R, Rouillé Y, Uchiyama Y, Dubremetz JF, Hoflack B
PAPER Koike M, Shibata M, Sunabori T, Yamaguchi J, Sakimura K, Komatsu M, Tanaka K, Uchiyama Y
COMMENT One of the most important questions related to the role of DAM (MGnD) microglia is their contribution to plaque pathology and disease progression in AD. The study by Hu and colleagues is a valuable contribution to our understanding of the role of early de